NanoSphere Health Sciences Inc. (NSHSF)
USD 0.04
(-60.0%)
USD 0.04
(-60.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.56 Million USD | 14.17% |
| 2022 | 1.37 Million USD | 13.57% |
| 2021 | 1.2 Million USD | -19.95% |
| 2020 | 1.5 Million USD | 20.41% |
| 2019 | 1.25 Million USD | 160.34% |
| 2018 | 481.37 Thousand USD | 187.56% |
| 2017 | 167.4 Thousand USD | -29.21% |
| 2016 | 236.47 Thousand USD | -12.47% |
| 2015 | 270.15 Thousand USD | 17.34% |
| 2014 | 230.22 Thousand USD | -51.25% |
| 2013 | 472.24 Thousand USD | -6.27% |
| 2012 | 503.85 Thousand USD | 83.44% |
| 2011 | 274.66 Thousand USD | 231.65% |
| 2010 | 82.81 Thousand USD | 446.03% |
| 2009 | 15.16 Thousand USD | -92.25% |
| 2008 | 195.61 Thousand USD | -85.97% |
| 2007 | 1.39 Million USD | 12799.33% |
| 2006 | 10.8 Thousand USD | 93.06% |
| 2005 | 5596.69 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.66 Million USD | 4.33% |
| 2024 Q1 | 1.59 Million USD | 1.72% |
| 2023 FY | 1.56 Million USD | 14.17% |
| 2023 Q1 | 1.4 Million USD | 2.32% |
| 2023 Q2 | 1.49 Million USD | 6.21% |
| 2023 Q3 | 1.5 Million USD | 0.7% |
| 2023 Q4 | 1.56 Million USD | 4.32% |
| 2022 Q2 | 1.3 Million USD | 2.23% |
| 2022 FY | 1.37 Million USD | 13.57% |
| 2022 Q4 | 1.37 Million USD | 7.26% |
| 2022 Q3 | 1.27 Million USD | -2.18% |
| 2022 Q1 | 1.27 Million USD | 5.88% |
| 2021 FY | 1.2 Million USD | -19.95% |
| 2021 Q2 | 1.66 Million USD | 7.25% |
| 2021 Q3 | 1.15 Million USD | -30.45% |
| 2021 Q1 | 1.55 Million USD | 2.96% |
| 2021 Q4 | 1.2 Million USD | 4.23% |
| 2020 Q4 | 1.5 Million USD | 7.45% |
| 2020 Q1 | 1.33 Million USD | 6.71% |
| 2020 Q2 | 1.36 Million USD | 2.29% |
| 2020 Q3 | 1.4 Million USD | 2.66% |
| 2020 FY | 1.5 Million USD | 20.41% |
| 2019 Q1 | 506.37 Thousand USD | 5.19% |
| 2019 FY | 1.25 Million USD | 160.34% |
| 2019 Q2 | 671.82 Thousand USD | 32.67% |
| 2019 Q3 | 1.02 Million USD | 52.66% |
| 2019 Q4 | 1.25 Million USD | 22.19% |
| 2018 Q4 | 481.37 Thousand USD | -36.18% |
| 2018 FY | 481.37 Thousand USD | 187.56% |
| 2018 Q3 | 754.28 Thousand USD | 989.68% |
| 2018 Q2 | 69.22 Thousand USD | 16.91% |
| 2018 Q1 | 59.21 Thousand USD | -64.63% |
| 2017 FY | 167.4 Thousand USD | -29.21% |
| 2017 Q3 | 103.74 Thousand USD | 63.53% |
| 2017 Q2 | 63.43 Thousand USD | -64.97% |
| 2017 Q1 | 181.09 Thousand USD | -23.42% |
| 2017 Q4 | 167.4 Thousand USD | 61.36% |
| 2016 FY | 236.47 Thousand USD | -12.47% |
| 2016 Q1 | 281.38 Thousand USD | 4.16% |
| 2016 Q3 | 191.37 Thousand USD | -32.87% |
| 2016 Q2 | 285.09 Thousand USD | 1.32% |
| 2016 Q4 | 236.47 Thousand USD | 23.57% |
| 2015 Q1 | 249.62 Thousand USD | 8.43% |
| 2015 Q3 | 237.3 Thousand USD | -7.27% |
| 2015 Q4 | 270.15 Thousand USD | 13.84% |
| 2015 FY | 270.15 Thousand USD | 17.34% |
| 2015 Q2 | 255.89 Thousand USD | 2.51% |
| 2014 Q3 | 199.84 Thousand USD | -65.21% |
| 2014 FY | 230.22 Thousand USD | -51.25% |
| 2014 Q4 | 230.22 Thousand USD | 15.2% |
| 2014 Q1 | 503.08 Thousand USD | 6.53% |
| 2014 Q2 | 574.36 Thousand USD | 14.17% |
| 2013 Q4 | 472.24 Thousand USD | 46.77% |
| 2013 Q3 | 321.75 Thousand USD | 28.29% |
| 2013 Q2 | 250.8 Thousand USD | -26.89% |
| 2013 Q1 | 343.07 Thousand USD | -31.91% |
| 2013 FY | 472.24 Thousand USD | -6.27% |
| 2012 Q3 | 266.96 Thousand USD | 8.06% |
| 2012 Q1 | 205.58 Thousand USD | -25.15% |
| 2012 FY | 503.85 Thousand USD | 83.44% |
| 2012 Q4 | 503.85 Thousand USD | 88.74% |
| 2012 Q2 | 247.05 Thousand USD | 20.17% |
| 2011 Q2 | 134.39 Thousand USD | 60.37% |
| 2011 Q3 | 176.02 Thousand USD | 30.98% |
| 2011 FY | 274.66 Thousand USD | 231.65% |
| 2011 Q1 | 83.8 Thousand USD | 1.19% |
| 2011 Q4 | 274.66 Thousand USD | 56.03% |
| 2010 FY | 82.81 Thousand USD | 446.03% |
| 2010 Q3 | 18.9 Thousand USD | 46.1% |
| 2010 Q1 | 22.55 Thousand USD | 48.74% |
| 2010 Q4 | 82.81 Thousand USD | 338.09% |
| 2010 Q2 | 12.93 Thousand USD | -42.64% |
| 2009 Q2 | 169.04 Thousand USD | 0.74% |
| 2009 Q1 | 167.79 Thousand USD | -14.22% |
| 2009 FY | 15.16 Thousand USD | -92.25% |
| 2009 Q3 | 177.02 Thousand USD | 4.72% |
| 2009 Q4 | 15.16 Thousand USD | -91.43% |
| 2008 Q3 | 947.32 Thousand USD | -6.93% |
| 2008 Q1 | 951.34 Thousand USD | -31.74% |
| 2008 Q4 | 195.61 Thousand USD | -79.35% |
| 2008 FY | 195.61 Thousand USD | -85.97% |
| 2008 Q2 | 1.01 Million USD | 6.99% |
| 2007 Q1 | 78.19 Thousand USD | 623.67% |
| 2007 Q3 | 550.2 Thousand USD | -35.33% |
| 2007 Q4 | 1.39 Million USD | 153.32% |
| 2007 FY | 1.39 Million USD | 12799.33% |
| 2007 Q2 | 850.82 Thousand USD | 988.11% |
| 2006 Q3 | 2049.08 USD | -1.93% |
| 2006 Q1 | 10.57 Thousand USD | 88.9% |
| 2006 FY | 10.8 Thousand USD | 93.06% |
| 2006 Q4 | 10.8 Thousand USD | 427.31% |
| 2006 Q2 | 2089.39 USD | -80.24% |
| 2005 FY | 5596.69 USD | 0.0% |
| 2005 Q3 | 32.68 Thousand USD | 0.0% |
| 2005 Q4 | 5596.69 USD | -82.88% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5609.828% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 83.452% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.839% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -93.668% |
| Rebus Holdings, Inc. | 5.24 Million USD | 70.119% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 97.346% |
| Qrons Inc. | 1.48 Million USD | -5.217% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -27.741% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.909% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3404.513% |
| Skye Bioscience, Inc. | 14.07 Million USD | 88.869% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 97.061% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 83.653% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -271.56% |
| SQZ Biotechnologies Company | 50.03 Million USD | 96.87% |
| Intellipharmaceutics International Inc. | 12 Million USD | 86.956% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 59.33% |
| Mesoblast Limited | 188.44 Million USD | 99.169% |
| Marizyme, Inc. | 26.67 Million USD | 94.128% |
| Genus plc | 485 Million USD | 99.677% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 73.191% |
| Pharming Group N.V. | 244.07 Million USD | 99.358% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 22.076% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 37.751% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 58.78% |
| ContraFect Corporation | 32.53 Million USD | 95.185% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 20.942% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 59.077% |
| IMV Inc. | 37.93 Million USD | 95.871% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 86.701% |
| MultiCell Technologies, Inc. | 1617.67 USD | -96729.205% |
| ONE Bio Corp. | 27.49 Million USD | 94.303% |
| Accustem Sciences Inc. | 1.07 Million USD | -45.137% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.977% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 25.942% |
| Q BioMed Inc. | 8.13 Million USD | 80.74% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 98.111% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 69.561% |
| Biomind Labs Inc. | 1.49 Million USD | -4.522% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.681% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 82.677% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 91.489% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -9.242% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1002.345% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -678.843% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 72.739% |
| GB Sciences, Inc. | 5.41 Million USD | 71.087% |
| Alpha Cognition Inc. | 7.16 Million USD | 78.138% |
| HST Global, Inc. | 593.59 Thousand USD | -163.881% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -24.395% |
| Halberd Corporation | 728.71 Thousand USD | -114.949% |
| Enzolytics Inc. | 365.26 Million USD | 99.571% |
| Agentix Corp. | 2.51 Million USD | 37.608% |
| Resverlogix Corp. | 67.39 Million USD | 97.676% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -86.755% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.648% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 8.613% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 93.67% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 86.841% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 57.263% |
| AVAX Technologies, Inc. | 3.99 Million USD | 60.779% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5581.661% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.882% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -556.338% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 58.054% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -130.067% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 42.235% |
| Kadimastem Ltd | 3.5 Million USD | 55.309% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2240.356% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 96.884% |
| BioStem Technologies, Inc. | 15.9 Million USD | 90.151% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -237.073% |
| LadRx Corporation | 2.2 Million USD | 28.818% |
| Cell Source, Inc. | 15.8 Million USD | 90.09% |
| Regen BioPharma, Inc. | 5.45 Million USD | 71.299% |
| Regen BioPharma, Inc. | 5.45 Million USD | 71.299% |
| NovAccess Global Inc. | 7.86 Million USD | 80.073% |
| Affymax, Inc. | 8.87 Million USD | 82.343% |
| Itoco Inc. | 1.65 Million USD | 5.249% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 23.65% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 74.105% |
| Mobile Lads Corp. | 1.31 Million USD | -19.252% |
| CytoDyn Inc. | 127.89 Million USD | 98.775% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3647.403% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 85.819% |
| SYBLEU INC | 681.41 Thousand USD | -129.872% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 74.33% |
| International Stem Cell Corporation | 5.27 Million USD | 70.317% |
| Bioxytran, Inc. | 3.24 Million USD | 51.796% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -150.296% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 66.075% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 96.179% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 92.965% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | 22.663% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 71.406% |
| Neutra Corp. | 973.52 Thousand USD | -60.897% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 94.601% |
| PureTech Health plc | 125.58 Million USD | 98.753% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 58.309% |
| IXICO plc | 1.9 Million USD | 17.572% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 92.37% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.484% |
| CSL Limited | 18.62 Billion USD | 99.992% |
| Cellectis S.A. | 249.36 Million USD | 99.372% |